Company intelligence / Profile preview

COSMO GROUP

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Cosmo Pharmaceuticals has six approved drugs and two approved medical devices. Its products address gastrointestinal diseases, dermatology conditions like acne and androgenetic alopecia, and healthtech solutions such as AI-powered endoscopic tools. The company’s proprietary MMX® technology enables targeted drug delivery to the colon. Recent clinical advances include phase III trials in androgenetic alopecia and global regulatory progress with new approvals in Japan, Canada, China, and Europe.

Therapeutic areas: DermatologyGastroenterologyOncologyInfectious Diseases
Modalities: Small moleculeBiologicDevice
Industry: Biotech

Drug pipeline

1 asset

Propofol, Benzodiazepine, and Opioid Combination

Unknown

Partnerships

Shire plc/TakedaFerring PharmaceuticalsDr. Falk Pharma GmbHAdalvo Ltd.China Medical System Holdings Ltd.Medtronic plc

Beyond the preview

Go deeper on COSMO GROUP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COSMO GROUP.

Explore the full profile